Mar 13, 2005

Integra LifeSciences Reports Fourth Quarter and Full Year 2004 Financial Results

PLAINSBORO, N.J., March 13, 2005 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its fourth quarter and full year 2004 revenues and earnings. Product revenues in the fourth quarter of 2004 were $61.8 million, reflecting an increase of $14.9 million, or 32%, over the fourth quarter of 2003. Product revenues for the full year ended December 31, 2004 increased by $61.8 million to $228.5 million, a 37% increase over the prior year.

Excluding recently acquired product lines, fourth quarter 2004 product revenues increased by $9.2 million, or 20%, over the prior year period, and full year 2004 product revenues increased by $32.7 million, or 23%, over the prior year.

Total revenues for the quarter increased over the prior year period by $2.8 million to $61.8 million. Total revenues for the full year ended December 31, 2004 increased by $44.2 million to $229.8 million.

We reported net income of $9.8 million, or $0.30 per diluted share, for the fourth quarter of 2004, compared to net income of $9.2 million, or $0.28 per diluted share in the fourth quarter of 2003. Net income for the year ended December 31, 2004 was $17.2 million, or $0.55 per diluted share, compared to $26.9 million, or $0.86 per diluted share, for the year ended December 31, 2003.

"We are very pleased with our performance in the fourth quarter and for the year," said Stuart M. Essig, Integra's President and Chief Executive Officer. "Organic revenue growth exceeded our long-term objective of 18%, and our corporate gross margin continued to build in keeping with our expectations. More importantly, we transformed Integra LifeSciences this year in the area of information technology. Our continuing implementation of an enterprise business system will streamline our ability to grow both organically and through acquisitions and strategic partnerships. We have made good on our ambition to accelerate product development, having launched significant new products in dural regeneration, adhesion prevention, nerve repair, neuromonitoring, cranial reconstruction and shunting for normal pressure hydrocephalus. We continued to cut costs and improve margins through plant consolidations. Finally, we have focused our Reconstructive Surgery sales force on the extremities, with exciting new products in the treatment of wounds and the surgical reconstruction of the foot and ankle."

This quarter, as required by the recently adopted Emerging Issues Task Force (EITF) Issue No. 04-08, The Effect of Contingently Convertible Debt on Diluted Earnings per Share, we treated the unissued shares underlying our contingently convertible notes issued in March 2003 as if such shares were issued and outstanding, using the "if-converted" accounting method, for the purposes of calculating earnings per share. As also required by EITF 04-08, we restated diluted earnings per share for all prior periods back to the issuance of this debt to conform to this new accounting standard.

The adoption of EITF 04-08 reduced earnings per share by $0.01 for the fourth quarter ended December 31, 2004, and by $0.02 for both the fourth quarter and year ended December 31, 2003. It had no impact on earnings per share for the full year 2004.

Our revenues for the periods were as follows:





Three Months Year Ended December 31, Ended December 31, 2004 2003 2004 2003 ---- ---- ---- ---- Product Revenue: Monitoring products $12,517 $11,466 $48,217 $44,229 Implants 19,851 14,325 78,418 53,301 Instruments 22,685 15,422 77,667 47,168 Private label products 6,709 5,648 24,188 21,997 -------- -------- -------- ------- Total Product Revenue 61,762 46,861 228,490 166,695 Other revenue 49 12,164 1,335 18,904 -------- -------- -------- ------- Total Revenue $61,811 $59,025 $229,825 $185,599

Increased sales of our drainage systems and intracranial monitoring products, including our Camino® and LICOX® monitoring systems, provided most of the year-over-year growth in monitoring product revenues.

Continued strong year-over-year growth in sales of our DuraGen® Dural Graft Matrix, DuraGen Plus™ Dural Regeneration Matrix, and our CSF management products, and direct selling of the INTEGRA® Dermal Regeneration Template and INTEGRA™ Bilayer Matrix Wound Dressing accounted for most of the increase in implant product revenues.

Sales of recently acquired product lines contributed $5.7 million of the year-over-year increase in instrument revenues for the fourth quarter. Increased sales of our JARIT® and Ruggles™ surgical instrument lines provided the remainder of the growth in instrument product revenues.

The increase in revenues attributable to our remaining private label products, including the Absorbable Collagen Sponge that we supply for use in Medtronic's INFUSE™ bone graft product, more than offset the removal of INTEGRA® Dermal Regeneration Template revenues from our private label products category.

Changes in foreign currency exchange rates contributed $0.7 million to our quarterly year-over-year product revenue growth.

Gross margin on product revenues in the fourth quarter of 2004 was 62.4%. Our gross margin was positively affected by changes in the mix of our products sold during the quarter and by the resumption of direct sales of the INTEGRA® Dermal Regeneration Template in 2004.

Research and development expense decreased from $4.8 million in the fourth quarter of 2003 to $3.6 million in the current period. Selling, general and administrative expense increased by $0.9 million to $20.3 million in the fourth quarter of 2004, but decreased as a percentage of product revenues to 33% from 41% in the prior year period. Selling, general and administrative expense in the fourth quarter of 2004 included costs associated with the closing of our distribution facility in New Jersey and the transfer of distribution functions to Nevada, and additional spending on Integra's enterprise business system implementation and Sarbanes-Oxley 404 compliance activities.

We reported net interest income of $95,000 in the fourth quarter of 2004, as compared to net interest income of $81,000 in the prior year period. Other income in the fourth quarter of 2004 was $2.3 million and included a $1.4 million gain related to the change in the fair value of the foreign exchange collar contract we executed in November 2004 upon agreeing to acquire Newdeal Technologies SA.

Our cash and investments totaled $196.0 million at December 31, 2004.

We are updating our expectations for total revenues, gross margin and earnings per share for 2005 and providing our initial guidance for 2006. In accordance with our usual practice, our expectations for 2005 and 2006 financial performance do not include the impact of acquisitions or other strategic corporate transactions that have not yet closed.

Total revenues in 2005 are expected to be between $290 million and $300 million. Total revenues in 2006 are expected to be between $345 million and $355 million. Consolidated gross margin is expected to increase to 64% and 66% of total revenues in 2005 and 2006, respectively. Earnings per diluted share are expected to be within a range of $1.38 to $1.42 per share in 2005. Earnings per diluted share are expected to be within a range of $1.65 to $1.75 per share in 2006. Our guidance for the first quarter of 2005 is for total revenues in the range of $65 million to $68 million and earnings per diluted share of $0.29 to $0.31. Our expectation ranges for full year 2005 and 2006 earnings per share do not reflect the impact of expensing stock options beginning July 1, 2005 under the accounting standard recently issued by the Financial Accounting Standards Board (FASB).

We have scheduled a conference call for 9:00 am EST tomorrow, March 14, 2005, to discuss the financial results for the fourth quarter of 2004 and forward-looking financial guidance. The call is open to all listeners and will be followed by a question and answer session. Access to the live call is available by dialing (973) 935-8511 or through a listen-only webcast via a link provided on the home page of Integra's website at www.Integra-LS.com. A replay of the conference call will be accessible starting one hour following the live event. Access to the replay is available through March 28, 2005 by dialing (973) 341-3080 (access code 5630772) or through the webcast accessible on our home page.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have research, manufacturing and distribution facilities located throughout the world. We have approximately 1,200 employees. Please visit our website at (http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning future financial performance, including projections for revenues, gross margins, earnings per share and cash flows. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, our ability to maintain relationships with customers of acquired entities, physicians' willingness to adopt our recently launched and planned products and our ability to secure regulatory approval for products in development may adversely affect our future product revenues; our ability to increase sales and product volumes may adversely affect our future gross margins; our ability to integrate acquired businesses, increase product sales and gross margins, and control non-product costs may affect our earnings per share; and our future net income results and our ability to effectively manage working capital may affect our future cash flows. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2003 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Regulation G, "Conditions for Use of Non-GAAP Financial Measures," and other provisions of the Securities Exchange Act of 1934, as amended, define and prescribe the conditions for the use of certain non-GAAP financial information. In this news release, we provide "quarterly year-over-year growth in product revenues excluding recently acquired product lines" and "annual year-over-year growth in product revenues excluding recently acquired product lines", which are non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is provided in the tables of financial information contained at the end of this news release.

Non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. Management believes that these non-GAAP financial measures are important supplemental information to investors which reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations, provides a more complete understanding of factors and trends affecting our ongoing business and operations. Management strongly encourages investors to review our financial statements and filed reports in their entirety and to not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names.





INTEGRA LIFESCIENCES HOLDINGS CORPORATION (In thousands, except per share data) (UNAUDITED)

Statement of Operations Data:

Three Months Ended December 31, 2004 2003 ---- ----

Product revenue $61,762 $46,861 Other revenue 49 12,164 ------ ------ Total revenue 61,811 59,025

Cost of product revenue 23,221 20,935 Research and development 3,556 4,772 Selling, general and administrative 20,264 19,354 Amortization 1,139 968 ------ ------ Total costs and expenses 48,180 46,029

Operating income 13,631 12,996

Interest income, net 95 81 Other income, net 2,250 1,962 ------ ------

Income before income taxes 15,976 15,039 Provision for income taxes 6,137 5,867 ------ ------ Net income $9,839 $9,172 ======= =======

Diluted earnings per share $0.30 $0.28

Diluted weighted average common shares outstanding 34,842 34,174





INTEGRA LIFESCIENCES HOLDINGS CORPORATION (In thousands, except per share data) (UNAUDITED)

Statement of Operations Data:

Year Ended December 31,

2004 2003 ---- ----

Product revenue $228,490 $166,695 Other revenue 1,335 18,904 -------- -------- Total revenue 229,825 185,599

Cost of product revenue 87,299 70,598 Research and development 14,121 12,815 Selling, general and administrative 99,360 59,459 Amortization 4,266 3,080 -------- -------- Total costs and expenses 205,046 145,952

Operating income 24,779 39,647

Interest income, net 555 471 Other income, net 2,674 3,071 -------- -------- Income before income taxes 28,008 43,189 Provision for income taxes 10,811 16,328 -------- -------- Net income $17,197 $26,861 ======== ======== Diluted earnings per share $0.55 $0.86

Diluted weighted average common shares outstanding 31,102 33,104





INTEGRA LIFESCIENCES HOLDINGS CORPORATION (In thousands, except per share data) (UNAUDITED)



Condensed Balance Sheet Data:

December 31, December 31, 2004 2003 ---- ---- Cash and marketable securities, including non-current portion $195,982 $206,743 Accounts receivable, net 46,765 28,936 Inventory, net 55,947 41,046 Total assets 456,713 412,526

Current liabilities 24,234 20,618 Long-term debt 118,900 119,257 Total liabilities 148,890 143,996 Stockholders' equity 307,823 268,530



RECONCILIATION OF NON-GAAP FINANCIAL MEASURE TO THE MOST COMPARABLE GAAP MEASURE:



A. Quarterly year-over-year growth in product revenues excluding recently acquired product lines

Excluding recently acquired product lines, fourth quarter 2004 product revenues increased by $9.2 million, or 20%, over the prior year period.

Quarter Ended December 31, Increase 2004 2003 $ % -------- -------- ------- ----- ($ in thousands) Total product revenues, as reported $ 61,762 $ 46,861 $14,901 32% Less: Product revenues acquired in 2004 5,249 -- 5,249 N/A Product revenues acquired in 2003 1,158 721 437 61% -------- -------- ------- ----- Product revenues excluding acquired products $ 55,355 $ 46,140 $ 9,215 20%



B. Annual year-over-year growth in product revenues excluding recently acquired product lines

Excluding recently acquired product lines, full year 2004 product revenues increased by $32.7 million, or 23%, over the prior year.

Year Ended December 31, Increase 2004 2003 $ % -------- -------- ------- ----- ($ in thousands) Total product revenues, as reported $228,490 $166,695 $61,795 37% Less: Product revenues acquired in 2004 13,633 -- 13,633 N/A Product revenues acquired in 2003 39,897 24,476 15,421 63% -------- -------- ------- ----- Product revenues excluding acquired products $174,960 $142,219 $32,741 23%

CONTACT:



Integra LifeSciences Holdings Corporation
John Bostjancic
Vice President, Corporate Controller
(609) 936-2239
jbostjancic@integra-ls.com



Maria Platsis
Senior Director of Investor Relations
and Corporate Development
(609) 936-2333
mplatsis@integra-ls.com